It is estimated that medical and recreational cannabis sales could exceed $33.6 billion with an additional economic impact of $100.8 billion by the end of 2023. The industry is maturing beyond its early days following legalization and is leaving behind the stigmas and...
Thinking | 15 May 2024 Source: https://hallandwilcox.com.au/thinking/navigating-regulatory-requirements-promoting-and-advertising-medicines-including-medicinal-cannabis/ By Alison Choy Flannigan and James Blok Introduction The increased use of relatively new...
On April 30, 2024, the Associated Press (AP) reported the Drug Enforcement Administration (DEA) will propose a rule to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). More specifically, the Department of Justice (DOJ),...
Via Mondaq The recent Labour Appeal Court (LAC) decision in the case of Bernadette Enever vs Barloworld Equipment South Africa, a division of Barloworld South Africa (Pty) Ltd (JA86/22) [2024] LAC… Clearing the Haze: The Labour Appeal Court’s Judgment on Cannabis in...
By Jason Adelstone Apr 29, 2024 After listening to the House Oversight and Accountability Committee Hearing with the Commissioner of the FDA on April 11, one conclusion was reinforced—opponents of marijuana reform are misinformed and rely on misstating facts to...
By Justin Henry May 2, 2024 The American Lawyer The likelihood of marijuana’s federal reclassification to Schedule III status has Big Law leaders eyeing opportunities to expand relationships with clients who have historically lacked the same tax benefits and...